Multi-Chain CAR Signaling Architecture for Stronger T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chimeric antigen receptors (CARs) for T-cell therapy in cancer treatment do not effectively enhance T-cell activation, target cell killing, and cytokine secretion, particularly when relying solely on CD3 and CD3ζ intracellular signaling domains.
Innovation Solution
Development of single-chain and multi-chain chimeric antigen receptors incorporating specific combinations of intracellular signaling domains, including DAP-10 or DAP12, 4-1BB, CD27, OX40, CD28, and ITAM, to improve T-cell activation and cytokine secretion, with antigen-binding domains targeting tumor-specific antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chimeric antigen receptors include only CD3 and CD3ζ intracellular signaling domains, then the CAR structure is simple, but T-cell activation and cytokine secretion are insufficient
Solution Approach 1:
The patent combines multiple intracellular signaling domains (DAP-10, DAP12, 4-1BB, CD27, OX40, CD40, CD28, GITR, CD2, CD5, ICAM-1, Lck, TNFR-I, TNFR-II, FasR, CD30, ICOS, LIGHT, NKG2C, and B7-H3) with the ITAM motif to create enhanced CAR constructs. This merging of multiple signaling components into a unified CAR structure resolves the contradiction by achieving reliable T-cell activation through combined signaling pathways while maintaining a manageable single-chain or multi-chain polypeptide architecture.
Solution Approach 2:
The patent employs composite signaling domain architectures where different intracellular domains are combined in specific configurations (single-chain or multi-chain formats). These composite structures integrate diverse signaling functions (co-stimulation, activation, and cytokine secretion enhancement) into unified CAR molecules, achieving reliable T-cell activation through the synergistic effects of multiple signaling components.
2Reliability
If chimeric antigen receptors use only CD3 and CD3ζ domains, then the CAR design is straightforward, but target cell killing effectiveness is limited
Solution Approach 1:
The patent merges multiple intracellular signaling domains known to enhance cytotoxicity (such as DAP-10, DAP12, 4-1BB, and CD28) with the essential CD3ζ ITAM-containing domain. This combination creates CAR constructs that achieve superior target cell killing through integrated signaling pathways that enhance T-cell cytotoxic granule release and perforin/granzyme activity, while the modular design keeps the overall structure manageable.
Solution Approach 2:
The patent introduces dynamic signaling capabilities through multiple intracellular domains that can be activated in sequence or simultaneously upon antigen engagement. The combination of domains allows for dynamic signal amplification and sustained T-cell activation, enhancing target cell killing effectiveness through time-dependent signaling events while maintaining structural organization through defined domain arrangements.
3Reliability
If chimeric antigen receptors include only CD3 and CD3ζ domains, then the CAR construction is simple, but cytokine secretion is insufficient
Solution Approach 1:
The patent combines intracellular domains known to promote cytokine production (such as CD28, 4-1BB, OX40, and CD27) with the ITAM-containing CD3ζ domain. This merging creates CAR constructs that effectively trigger IL-2, interferon-gamma, and TNFα secretion through integrated signaling pathways that activate transcription factors and cytokine gene expression, while the modular domain architecture keeps construction complexity manageable.
Solution Approach 2:
The patent uses intermediate signaling domains (such as DAP-10, DAP12, and various co-stimulatory domains) that act as mediators between antigen recognition and cytokine secretion. These intermediary domains translate the initial antigen-binding event into sustained signaling cascades that activate cytokine gene expression, effectively bridging the gap between antigen recognition and cytokine release while maintaining a structured domain organization.
Data Source
AI summary
Provided herein are single-chain and multi-chain chimeric antigen receptors, nucleic acids encoding the same, and mammalian cells expressing the same. Also provided are methods of treating a cancer in a subject using a mammalian cell expressing any of these single-chain and multi-chain chimeric antigen receptors.